Human In Vitro Developmental Toxicity Assay Combined with a Read-Across Approach for Chemical Assessment – FutureTox III (2015)
Mar 21, 2017Presented at FutureTox III: Bridges for Translation in Arlington, Virginia in November 2015 by Stemina’s Associated Director of Toxicology, Jessica Palmer. The reproductive and developmental toxicity requirements for registering chemical substances under REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) using whole-animal models could cost up to $8 billion and require the use of up
A Metabolic Profile of Autism Spectrum Disorder from Autism Phenome Project Patient Plasma – IMFAR 2015 [PDF]
Mar 23, 2016Presented at the International Meeting for Autism Research, May 2015, in Salt Lake City, Utah. We The diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. Patients can be reliably diagnosed through behavioral testing at about 2 years of age. However, in the United States the
A Biomarker-Based Human Stem Cell Assay Applied for Ranking a Retinoid Series Based on Relative Developmental Toxicity Potential
Feb 20, 2016Presented at the Society of Toxicology’s 55th Annual Meeting and ToxExpo, March 2015, in San Diego, California. We previously developed an in vitro, biomarker-based, human induced pluripotent stem (iPS) cell-based assay to screen compounds for developmental toxicity. The assay measures changes in two amino acids (ornithine and cystine) involved in cell proliferation and differentiation. This
Evaluation of 1066 Toxcast Chemicals in a Human Sem Cell Assay for Developmental Toxicity
Jan 3, 2016Presented at the Society of Toxicology’s 55th Annual Meeting and ToxExpo, March 2015, in San Diego, California. EPA’s ToxCast program has generated data on a battery of 821 in vitro endpoints for 1066 compounds including pharmaceuticals, natural products, pesticidal active ingredients, consumer use chemicals and industrial ingredients. To increase the diversity of in vitro assays
Toward Validation of a Human In Vitro Assay for Developmental Toxicity Assessment
Dec 15, 2015Presented at the 9th World Congress on Alternatives and Animal Use in the Life Sciences, August 2014, in Prague, Czech Republic. Innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animal models are required for the REACH initiative (Europe) and Tox21 initiative (US) to evaluate thousands of chemicals for safety.
A Biomarker Based Developmental Toxicity Screen Using Human Induced Pluripotent Stem Cells For Compound Prioritization
Nov 23, 2015Presented at the Society of Toxicology 53rd Annual Meeting, March 2014, in Phoenix, Arizona. Development of innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animal models in compound safety testing is critical to meet the safety requirements for multiple industries. The current initiatives in Europe (Registration, Evaluation, and Authorization
Establishment and Assessment of a New Human Embryonic Stem Cell Based Biomarker Assay for Developmental Toxicity Screening
Oct 21, 2015Presented at the 11th International Conference on Environmental Mutagens (ICEM), March 2013, in Foz do Ignassu, Brazil. Application of more predictive developmental toxicity screens would aid in reducing the prevalence of birth defects and increase pharmaceutical and chemical safety worldwide. Human embryonic stem (hES) cell technology provides an opportunity for innovative and robust alternative in
Stemina to receive National Institutes of Health grants
Sep 25, 2015Stemina Biomarker Discovery is getting two National Institutes of Health grants, one of which will let the Madison company start what it called the largest clinical study ever conducted into the metabolism of children with autism spectrum disorder (ASD).
Stemina Launches Large Autism Diagnostic Study
Sep 24, 2015With a new $2.7 million federal grant in hand, Stemina Biomarker Discovery has launched a 1,500-patient study of its experimental test to diagnose children with autism spectrum disorder. According to the company, it’s the largest clinical trial ever of this type of autism test—one that measures residues in the blood called metabolites.
Stemina Launches Autism Clinical Study
Sep 23, 2015Stemina Biomarker Discovery Inc. today announced the launch of the largest clinical study of the metabolism of children with autism spectrum disorder (ASD) ever conducted. The Children’s Autism Metabolome Project or “CAMP” study will enroll 1,500 subjects from six sites across the country. CAMP will attempt to confirm that sets of metabolic biomarkers can detect
Development of a Targeted Biomarker Assay to Predict Developmental Toxicity Using Induced Pluripotent Stem Cells
Jul 11, 2015Presented at the American College of Toxicology 34th Annual Meeting, November 2013, in San Antonio, Texas. Assessment of the developmental toxicity potential of new chemicals is both resource intensive and time consuming. Large numbers of laboratory animals are required and the predictive value of these decades-old tests has been challenged. Availability of more predictive developmental
A Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells
May 18, 2015Presented at the American College of Toxicology 33rd Annual Meeting, November 2012, in Orlando, Florida. Birth defects are the largest cause of infant morbidity and mortality in the United States. Teratogens, defined as substances that cause fetal abnormalities during development, are responsible for 5-10% of all birth defects. The application of more predictive developmental toxicity
Stemina Presents Poster with EPA at SOT
May 5, 2015Autism Speaks’s 2015 Autism Investment Conference (AIC2015) will take place on March 10-11, 2015 at the Seaport Hotel & World Trade Center in Boston, Massachusetts. The conference addresses the autism community’s most relevant and urgent needs. The program is structured into (8) individual sessions, each focusing on a different area of product or business development
Stemina to Present at IMFAR in Salt Lake City
Apr 14, 2015The International Meeting for Autism Research (IMFAR) is a scientific meeting to exchange and disseminate new scientific progress among ASD scientists and their trainees from around the world. Stemina’s Dr. Robert Burrier will be presenting his talk, “Effects of Metabolism Changes during Development on the Plasma Profile of ASD in Children” on Friday, May 15,
A High Throughput Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells
Mar 8, 2015Presented at the American College of Toxicology 33rd Annual Meeting, November 2012, in Orlando, Florida. Birth defects are the largest cause of infant morbidity and mortality in the United States. Teratogens, defined as substances that cause one or more fetal abnormalities during development, are responsible for 5-10% of all birth defects. Availability of more predictive
Beth Donley Interviewed by Xconomy
Nov 10, 2014In the latest attempt to find a better method for diagnosing autism, researchers at Madison, WI-based Stemina Biomarker Discovery and the University of California-Davis’ Mind Institute published study results Friday of an early-stage, blood-based test that they say identified autistic children with 81 percent accuracy.
Stemina Published in PLOS One
Nov 7, 2014Stemina Biomarker Discovery, Inc. today announced the publication of research conducted in collaboration with the MIND Institute at the University of California-Davis to identify biomarkers in the blood of children with autism spectrum disorders (ASD) that can distinguish them from typically developing children. The research is the first of its kind and has the potential
Metabolomics as a Tool for Discovery of Biomarkers of Autism Spectrum Disorder in the Blood Plasma of Children
Nov 7, 2014PLOS One (November 7, 2014) The diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. In the United States the average age of diagnosis is 4 years. Identifying metabolic biomarker signatures of ASD from blood samples offers an opportunity for development of diagnostic tests for detection
Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Pluripotent Stem Cell-Derived Cardiomyocytes
Oct 4, 2014Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for the withdrawal of 28% of FDA-approved drugs from the market. The development of better screening assays to predict cardiotoxicity is needed to enable the placement of safer drugs in the market and reduce adverse effects. Current
Stemina Receives Wisconsin Innovation Award
Aug 27, 2014Stemina was awarded a Wisconsin Innovation Award. About 120 nominations were received for the award. This was narrowed down to 10 award winners from around the state, featuring creative products and services from startups and large companies spanning biotech, software, manufacturing, and education.
Stemina to Present at WC9 Conference in Prague
Aug 25, 2014Stemina’s Beth Donley will present a poster titled “Toward Validation of a Human In Vitro Assay for Developmental Toxicity Assessment” at the 9th World Congress on Alternatives and Animal Use in the Life Sciences.
BrightStar Invests in Stemina
Mar 18, 2014Stemina Biomarker Discovery, is one of three Wisconsin businesses to win the first of the BrightStar Foundation’s investments.
Key Metabolic Pathway Changes in Human Embryonic Stem Cells Exposed to Methyl Parathion and Methyl Paraoxon
Jan 23, 2014Toxic industrial chemicals (TICs) represent a threat to soldiers, first responders and other civilians. One class of toxic industrial chemicals, pesticides, is particularly accessible and used widely in crop, industrial, and home applications. For many pesticides, including methyl parathion (MP), there is incomplete and sometimes conflicting information regarding the basic molecular toxicological consequences of exposure
EPA Awards Stemina $10M Contract
Jan 9, 2014Stemina Biomarker Discovery, Inc. announced that it has been awarded a contract by the United States Environmental Protection Agency under the EPA’s ToxCast initiative. The contract will generate up to $10,637,000 in revenue for Stemina over the next 5 years. Under the contract, Stemina will screen drugs and chemicals, using its devTOX toxicology tests, for
An Alternative Developmental Toxicity Screening Capability
Nov 3, 2013Birth defects are the leading cause of infant mortality but approximately 70%of birth defects have no known cause (CDC, 2005). Between 2 and 3% of birth defects are caused by teratogens, or substances that cause birth defects (Finnell, 1999). Pharmaceutical companies screen for developmental toxicity using animal models, yet these screens are only as little
Beth Donley to present at International Conference on Environmental Mutagens
Nov 1, 2013Stemina’s Beth Donley will present at the 11th International Conference on Environmental Mutagens in Foz do Iguassu, Brazil on November 5. Her poster, “Establishment and assessment of a new embryonic stem cell based biomarker assay for developmental toxicity screening,” can be viewed here:
Laura Egnash to present at ACT San Antonio
Oct 22, 2013Stemina’s Laura Egnash will present at the 34th American College of Toxicology annual conference in San Antonio, Texas on November 4 and 5. Her poster, “Development of a Targeted Biomarker Assay to Predict Developmental Toxicity Using Induced Pluripotent Stem Cells,” can be viewed here:
Stemina Published in Birth Defects Research
Oct 11, 2013Stemina’s paper, “Establishment and Assessment of a New Human Embryonic Stem Cell-Based Biomarker Assay for Developmental Toxicity Screening” was published in Birth Defects Research.
Beth Donley to present at BIO Investor Forum
Oct 7, 2013Stemina CEO Beth Donley will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, California.
Metabolomics Based Comparison of Human Embryonic and Induced Pluripotent Stem Cells to Predict Developmental Toxicity
Sep 25, 2013Induced pluripotent stem (iPS) cells are derived from the genetic manipulation of somatic cells. These cells are being investigated for use in place of hES cells due to the moral, ethical and political controversies that surround them. Human iPS cells are phenotypically and genetically similar to hES cells in many respects (i.e. morphology, proliferation, gene
Establishment and Assessment of a New Human Embryonic Stem Cell-Based Biomarker Assay for Developmental Toxicity Screening
Aug 1, 2013Birth Defects Research (Volume 98, Issue 4, August 2013, Pages 343-363) A metabolic biomarker-based in vitro assay utilizing human embryonic stem (hES) cells was developed to identify the concentration of test compounds that perturbs cellular metabolism in a manner indicative of teratogenicity. This assay is designed to aid the early discovery-phase detection of potential human
A Laboratory Information Management System (LIMS) for High-Throughput LC-MS Metabolomics-based Biomarker Discovery
Jul 31, 2013SteminaLIMS is a web-based laboratory management tool specifically designed to streamline the processes involved with metabolomics based biomarker discovery. The SteminaLIMS manages the entire stream of textual, numerical, statistical and graphical data including project information sample preparation and metadata, mass spectrometry data acquisition and analysis, file conversion, peak picking, statistical analysis, annotation, and small molecule
Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Jun 19, 2013Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for the withdrawal of 28% of FDA-approved drugs from the market. The development of better screening assays to predict cardiotoxicity is needed to enable the placement of safer drugs in the market and reduce adverse effects. Current
Alan Smith to present at Teratology Society Meeting
Jun 19, 2013Stemina’s Alan Smith will speak at the Teratology Society 53rd Annual Meeting in Tucson, Arizona. He will be presenting at the March of Dimes Symposium: Advances in the Genomic Sciences towards Public Understanding and Predicting Developmental Defects on Wednesday June 27th at 11:30 am.
Laura Egnash Presents at Agilent Users’ Meeting
Jun 8, 2013Stemina’s Laura Egnash presented at the Agilent Technologies users’ meeting at the 61st American Society of Mass Spectrometry annual conference. Her presentation, “Applying Metabolomics for Novel Biomarker Discovery and Commercial Assay Development,” can be viewed here:
Laura Egnash Speaks at ASMS Agilent Users Meeting
Jun 8, 2013Laura Egnash was invited to speak at the Agilent Users’ Meeting in Minneapolis on June 8, 2013 at the American Society of Mass Spectrometry annual conference. Follow the link at right to view her full presentation, “Applying Metabolomics for Novel Biomarker Discovery and Commercial Assay Development.”
Stemina Hosts Session at SOT 2013
May 29, 2013Stemina’s CEO, Beth Donley, presented Stemina’s new in vitro assay for prediction of developmental toxicity: devTOX quickPredict.
Stemina Published in ALTEX
Apr 18, 2013Stemina’s Beth Donley co-authored a paper, Metabolomics in Toxicology and Preclinical Research, in ALTEX. ALTEX is the offical journal of CAAT (the Johns Hopkins Center for Alternatives to Animal Testing), EUSAAT (the European Society for Alternatives to Animal Testing), the Transatlantic Think Tank for Toxicology (Baltimore, Utrecht, Konstanz), and the Doerenkamp chairs in Germany, India,
Discovery of Cancer Stem Cell Biomarkers Using Metabolomics
Apr 11, 2013Stemina Biomarker Discovery, Inc. has engaged in a study to discover metabolomic biomarkers that are potential indicators of drug efficacy against cancer stem cells (CSCs) for the establishment of novel drug screening assays. The primary cellular target used in this screen was cancer stem cells derived from glioblastoma multiforme (GBM), brain tumor stem cells (BTSCs),
Stemina to Sponsor Session at 2013 SOT Annual Meeting
Mar 6, 2013Stemina will sponsor a session at the 2013 SOT Annual Meeting titled “Human Embryonic Stem (hES) Cells for Predictive Toxicology.” The session is Wednesday from 10:30 to 11:30 in Room 007B. Stemina’s poster titled “A Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells” will be on display Tuesday from 9:00 to
Predictive Metabolism Based Model of Cardiomyopathy Using Human Embryonic Stem Cell Derived Cardiac Precursers
Feb 1, 2013Cardiomyopathy is a broad term to describe the deterioration of function of the myocardium (heart muscle) that disrupts the heart’s ability to pump blood. Cardiomyopathy can be a serious chemotherapy-related cardiac dysfunction that can lead to chronic heart failure. The underlying mechanism of chemotherapeutics (anthracyclines, taxanes) and kinase inhibitor-induced cardiomyopathies is unclear. While certain compounds
Stemina featured in InBusiness Magazine
Dec 7, 2012Stemina’s Beth Donley is featured in the December issue of InBusiness Magazine.
The ABCs of membrane transporters in health and disease (SLC series): Introduction
Nov 4, 2012Molecular Aspects of Medicine (Volume 34, 2013, Pages 95-107) The field of transport biology has steadily grown over the past decade and is now recognized as playing an important role in manifestation and treatment of disease. The SLC (solute carrier) gene series has grown to now include 52 families and 395 transporter genes in the
Stemina to Present Poster at ACT Annual Meeting
Nov 1, 2012Stemina is presenting its stem cell and metabolomics based developmental toxicity assay at the American College of Toxicology Annual Meeting in Orlando on November 5, 2012.
The sodium-dependent ascorbic acid transporter family SLC23
Sep 23, 2012Molecular Aspects of Medicine (Volume 34, 2013, Pages 436-454) Transporters for vitamin C and its oxidized form dehydroascorbic acid (DHA) are crucial to maintain physiological concentrations of this important vitamin that is used in a variety of biochemical processes. The human SLC23 family consists of the Na+-dependent vitamin C transporters SVCT1 (encoded by the SLC23A1
Metabolomics in Toxicology and Preclinical Research
Aug 15, 2012ALTEX: Alternatives to Animal Experimentation (Article in Press) Metabolomics, the comprehensive analysis of metabolites in a biological system, provides detailed information about the biochemical/physiological status of a biological system, and about the changes caused by chemicals. Metabolomics analysis is used in many fields, ranging from the analysis of the physiological status of genetically modified organisms
Metabolic Biomarkers of Prenatal Alcohol Exposure in Human Embryonic Stem Cell–Derived Neural Lineages
Aug 11, 2012Alcoholism: Clinical and Experimental Research (Volume 36, Issue 8, August 2012, Pages 1314-24) Fetal alcohol spectrum disorders (FASD) are a leading cause of neurodevelopmental disability. The mechanisms underlying FASD are incompletely understood, and biomarkers to identify those at risk are lacking. Here, we perform metabolomic analysis of embryoid bodies and neural lineages derived from human
Stemina to Present at Eurotox 2012
May 7, 2012Stemina is presenting its stem cell and metabolomics based assays at EuroTox in Stockholm in the Agilent sponsored session on June 19, 2012.
Stemina and ILS to Exhibit at Annual Teratology Meeting
Apr 18, 2012Stemina and its North American partner, ILS, will exhibit at the 52nd annual meeting of the Teratology Society in Baltimore June 23-27.
Stemina awarded third Phase I SBIR
Feb 24, 2012Stemina was awarded its third Phase I SBIR today. The study, entitled “Identification of Biomarkers of Cardiotoxicity Using Metabolomics Analysis on Human Pluripotent Stem Cell-Derived Cardiomyocytes,” was funded by the National Institute of General Medical Sciences. The purpose of this study is to alleviate the financial burden of compound attrition due to cardiotoxicity and to
A Roadmap for the Development of Alternative (Non-Animal) Methods for Systemic Toxicity Testing
Jan 26, 2012ALTEX: Alternatives to Animal Experimentation (Volume 29, Issue 1, January 2012, Pages 5-91) Systemic toxicity testing forms the cornerstone for the safety evaluation of substances. Pressures to move from traditional animal models to novel technologies arise from various concerns, including: the need to evaluate large numbers of previously untested chemicals and new products (such as
Stemina’s Paper Published in Toxicology and Applied Pharmacology
Nov 28, 2011Metabolomics analysis was performed on the supernatant of human embryonic stem (hES) cell cultures exposed to a blinded subset of 11 chemicals selected from the chemical library of EPA’s ToxCast™ chemical screening and prioritization research project. Metabolites from hES cultures were evaluated for known and novel signatures that may be indicative of developmental toxicity.
Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics
Nov 15, 2011Toxicology and Applied Pharmacology Volume 257, Issue 1, 15 November 2011, Pages 111-121 Metabolomics analysis was performed on the supernatant of human embryonic stem (hES) cell cultures exposed to a blinded subset of 11 chemicals selected from the chemical library of EPA’s ToxCast™ chemical screening and prioritization research project. Metabolites from hES cultures were evaluated
ILS and Stemina announce exclusive partnership for human stem cell based toxicology testing.
Nov 2, 2011ILS and Stemina Biomarker Discovery, Inc. announced today that the two companies have entered into a strategic partnership to advance Stemina’s stem cell based toxicology testing platform, beginning with devTOX. ILS will exclusively distribute Stemina’s platform in North America and the two companies will work jointly to further develop the platform.
CIT and Stemina Ink Deal in Europe
Nov 2, 2011Stemina announces the recent strategic partnership between Stemina and CIT in Evreux, France. Under this partnership, CIT will distribute Stemina’s assays in Europe leveraging CIT’s considerable reputation and expertise to bring Stemina’s cutting edge technology for predictive toxicology to the market.
Stemina Awarded Second Phase II SBIR
Feb 7, 2011Stemina received a 2 year contract to study biomarkers of teratogenicity and is a Phase II continuation of the original Phase I work performed for the National Science Foundation in 2010.
Stem cell scientists stress need for continued support of human embryonic stem cell research
Oct 26, 2010Concerned by election rhetoric that portrays adult stem cells as adequate substitutes for human embryonic stem cells, several leading scientists joined with a patient advocate and the founders of a growing biotechnology company Tuesday to set the record straight before voters head to the polls next week.
Stemina Receives $1 million Contract from NCI
Sep 30, 2010Stemina received a 2 year $1 million contract to study biomarkers of cancer stem cells and is a Phase II continuation of the original Phase I work performed for NCI in 2008 and 2009. This project will be conducted in collaboration with Mayo Clinic and the University of Wisconsin’s McArdle Cancer Center. Stemina will be
Stemina CEO Responds to Stem Cell Ruling and Wisconsin State Journal Article
Aug 25, 2010I wanted to take a minute to send you some accurate information about the facts as they relate to Stemina. Having worked on the legal and political aspects of this important technology since Dr. Thomson was the first to isolate hESC in 1998 at the University of Wisconsin while I served as General Counsel for
Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics
Aug 15, 2010Toxicology and Applied Pharmacology Volume 247, Issue 1, 15 August 2010, Pages 18-27. Teratogens, substances that may cause fetal abnormalities during development, are responsible for a significant number of birth defects. Animal models used to predict teratogenicity often do not faithfully correlate to human response. Here, we seek to develop a more predictive developmental toxicity
Stemina and Pioneer Hi-Bred Sign Research Agreement
Jun 1, 2010Under the collaboration, Stemina will use its proprietary metabolomics platform and expertise in discovery and validation of small molecules to identify biomarkers associated with specific plant traits.
Stemina Partners with Bristol-Myers Squibb
May 27, 2010A partnership with Bristol-Myers Squibb Co. will use Stemina’s products to evaluate whether drugs the New York pharmaceutical company is developing might be toxic to the heart.
Stemina Featured in GenomeWeb’s Startup Focus
May 27, 2010Leveraging one of the newer ‘omics fields along with stem cell technology, start-up firm Stemina Biomarker Discovery is looking to accelerate its work at developing metabolomic biomarkers for drug screening and efficacy and the detection of diseases.
Agilent Technologies Announces Collaboration with Stemina
May 24, 2010Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina’s metobolomic research. Agilent is providing a 1290 Infinity UHPLC system to separate stem cellular metabolites, coupled to a 6530 Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS) to identify those metabolites. Agilent also is providing Mass Profiler Professional software to help
Dr. Paul West Speaks at ASMS Agilent Users Meeting
May 22, 2010Paul West was invited to speak at the Agilent Users Meeting in Salt Lake City on May 22, 2010 at the American Society of Mass Spectrometry annual meeting. Follow the link at right to view his full presentation, “Discovering Biomarkers of Human Disease and Development Using Stem Cells and Metabolomics.”
Stemina Paper Accepted for Publication
May 5, 2010Toxicology and Applied Pharmacology accepted Stemina’s manuscript entitled “Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics” for publication. Read the abstract at the link below:
Dr. Paul West Presents Webinar
Sep 23, 2009Paul West was invited to present at a Genetic Engineering News & Biotechnology Webinar, “Advances in Compound Identification Using Metabolomics”. The primary focus of Dr. West’s presentation entitled “De Novo Metabolite Chemical Structure Determination” is metabolite chemical structure determination using LC-MS, accurate mass and MS-MS. The Webinar was presented on September 23, 2009.
Stemina and California Stem Cell form Collaboration
Sep 17, 2009California Sem Cell and Stemina Biomarker Discovery announce their collaboration to validate effectiveness of human embryonic stem cell-derived cardiomyocyte progenitors for use in predictive toxicology.
Promega and Stemina Biomarker Discovery Collaborate to Improve Techniques in Stem Cell Research
Sep 16, 2009Promega Corporation, a provider of innovative solutions and technical support, and Stemina Biomarker Discovery, Inc. announced today that they have entered into a collaborative research agreement. The collaboration will combine Stemina’s expertise in human embryonic stem (hES) cells with Promega’s expertise in biological reagents and related instrumentation for use in studying cellular and functional biology.
Stemina Launches Its First Commercial Product
Apr 29, 2009Madison start-up Stemina Biomarker Discovery Inc. has launched its first commercial product, which uses human embryonic stem cells to screen drugs for their likelihood to cause birth defects. The launch comes shortly after President Barack Obama lifted restrictions on stem cell research, opening up opportunities for companies like Stemina, which also this month launched its
Inc. August 2008
Aug 6, 2008EVER SINCE THE economy started slowing last year, business owners have been complaining about a lack of access to capital. Not Elizabeth Donley. The CEO of Stemina Biomarker Discovery and her co-founder, Gabriela Cezar, raised $1.5 million from angel investors in six months after entering their Madison, Wisconsin-based stem-cell-research company in a business plan competition
Forbes June 2008
Jun 25, 2008Gabriela Cezar of biotech startup Stemina is unraveling the chemistry of autism. DRUG DISCOVERY IS A CRUAL BUSINESS. A hundred thousand people die every year because of adverse drug side effects. Millions die too young because drugs just aren’t good enough. The problem is that scientists invent medicines to treat people, but they have to
Wisconsin Woman June 2008
Jun 2, 2008When Gabriela Cezar and Beth Donley are together, there’s a certain electricity in the room. At once they are both excited and serious, moving rapidly and casually from fashion talk to a story about partying with celeb Ben Stiller to yet the more pressing work going on behind the closed doors of their UW Research
Identification of Small Molecules from Human Embryonic Stem Cells Using Metabolomics
Dec 25, 2007Stem Cells and Development Volume 16, Issue 6, 25 December 2007, Pages 869-882 Metabolomics enables the discovery of small molecules that may serve as candidate biomarkers of pharmacological efficacy or toxicity. Biochemical pathways of human development are likely active in human embryonic stem (hES) cells and derivatives, since they recapitulate organogenesis in vitro. We hypothesized
Embryonic Stem Cells in Predictive Cardiotoxicity: Laser Capture Microscopy Enables Assay Development
Mar 2, 2006Toxicological Sciences Volume 90, Issue 1, March 2006, Pages 149-158 Embryonic stem (ES) cells offer unprecedented opportunities for in vitro drug discovery and safety assessment of compounds. Cardiomyocytes derived from ES cells enable development of predictive cardiotoxicity models to increase the safety of novel drugs. Heterogeneity of differentiated ES cells limits the development of reliable